Allouche Cyril 4
4 · Revance Therapeutics, Inc. · Filed Jan 2, 2019
Insider Transaction Report
Form 4
Allouche Cyril
Principal Financial Officer
Transactions
- Other
Common Stock
2018-12-31$17.11/sh+375$6,416→ 4,375 total
Footnotes (1)
- [F1]These shares were acquired by Mr. Allouche under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 31, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mr. Allouche purchased the maximum number of shares allowable under the Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2018.